. 2015 Aug 18;173(5):541–551. doi: 10.1530/EJE-15-0554
This work is licensed under a Table 4.
Summary of IGF1 SDS mean pharmacodynamic parameters (unadjusted).
| Dose | IGF1 (SDS) at 0 h Mean (s.d.) | Emax (SDS) Mean (s.d.) | TEmax (h) Median (range) |
|---|---|---|---|
| 3 mg (n=6) | 0.2 (1.1) | 1.1 (1.0) | 36.0 (24.0–72.0) |
| 10 mg (n=6) | −0.1 (0.6) | 1.4 (0.6) | 66.0 (36.0–168.0) |
| 25 mg (n=6) | 0.5 (0.7) | 2.4 (1.0) | 48.0 (36.0–72.0) |
| 35 mg (n=6) | −0.2 (0.4) | 2.6 (0.4) | 66.0 (60.0–72.0) |
| 50 mg (n=6) | 0.4 (0.8) | 3.4 (0.3) | 66.0 (60.0–96.0) |
| 70 mg (n=6) | 0.6 (0.5) | 3.0 (0.6) | 60.0 (48.0–72.1) |
| 100 mg (n=6) | −0.4 (1.0) | 3.3 (0.9) | 72.0 (72.0–96.0) |
| Pooled placebo (n=14) | 0.5 (0.7) | 1.2 (0.7) | 72.0 (48.0–672.0) |